Autoimmune Market Outlook to 2012
Pages: 216
Publisher: Business Insights
Date Published: August 2007
Format: PDF
Price: $2875
Overview
Autoimmune related disorders continue to maintain prominence within the global disease burden, having achieved a worldwide market growth of 9.4% over the 2002-06 period. However, the inherent threat of generic competition and novel product launches are forecast to transform the dynamics of the autoimmune market over the next 5 years. The autoimmune pipeline represents a key opportunity for drug development companies, with the potential for success largely attributable to substantial unmet demand, a significant patient population and the medical proclivity for long term treatments. In consequence, the effective exploitation of market potential is becoming increasingly crucial, and hinges upon drug developments that accurately reflect the shifting demographics of autoimmune disorders and unmet patient needs.
Autoimmune Market Outlook to 2012 is a new report published by Business Insights, examining how the competitive dynamics of major pharma companies will influence the market positions of products and shape the direction of future global autoimmunology. Market trends and leading brands of treatment are extensively profiled, while the most commercially promising R&D therapies are investigated and assessed to discover their sales potential. This report will also provide a comprehensive epidemiological analysis of the major indications and detailed product sales forecasts. Use this report to identify opportunities in the autoimmune pipeline, assess the dynamics of leading competitors and evaluate the impact of key trends across the global market.
Table of Contents
Executive Summary
Patient potential
Global market analysis
Pipeline analysis
Competitive landscape
Chapter 1 Epidemiology of the autoimmune therapeutic area
Summary
Introduction
Osteoarthritis and rheumatoid arthritis
Overview
Diagnosis, treatment and management
Epidemiology
Forecast epidemiology
Spondyloarthropathies
Overview
Diagnosis, treatment and management
Epidemiology
Forecast epidemiology
Lupus
Overview
Diagnosis, treatment and management
Epidemiology
Forecast epidemiology
Psoriasis
Overview
Diagnosis, treatment and management
Epidemiology
Forecast epidemiology
Crohn’s disease
Overview
Diagnosis, treatment and management
Epidemiology
Forecast epidemiology
Chapter 2 Global market analysis
Summary
Introduction
Market analysis by country
Licensing/generics trends
Market analysis by drug class
Leading brands dynamics
Key events in the autoimmune market
Immunosuppressants
Competitive dynamics of immunosuppressants
Leading brands of immunosuppressants
Key brands analysis
Immunosuppressants sales forecasts to 2012
Antirheumatic agents
Competitive dynamics of antirheumatic agents
Leading brands of antirheumatic agents
Key brands analysis
Antirheumatic sales forecasts to 2012
NSAIDs
Competitive dynamics of NSAIDs
Leading brands of NSAIDs
Key brands analysis
NSAIDs sales forecasts to 2012
Topical antirheumatics
Competitive dynamics of topical antirheumatics
Leading brands of topical antirheumatics
Topical antirheumatic sales forecasts to 2012
COX-II inhibitors
Competitive dynamics of COX-II inhibitors
Leading brands of COX-II inhibitors
Key brands analysis
COX-II inhibitors sales forecasts to 2012
Corticosteroids
Competitive dynamics of corticosteroids
Leading brands of corticosteroids
Corticosteroids sales forecasts to 2012
Total autoimmune sales forecasts to 2012
Chapter 3 Pipeline analysis
Summary
Introduction
Key trends in R&D
Biologics
Combination drugs
Fully human monoclonal antibodies
B-cell depleting therapies
The autoimmune pipeline
Leading drugs in development
Profiles of key pipeline products
Phase III compounds
Licofelone (ML3000)
Cimzia (certolizumab pegol)
LymphoStat-B (belimumab)
Golimumab (CNTO 148)
R1594 / PRO70769 (ocrelizumab)
Recently marketed drugs
Actemra (tocilizumab)
Rituxan (rituximab)
Taclonex (calcipotriene/betamethasone)
Panaclar/BG-12
Pipeline forecasts
Factors affecting forecasts
Autoimmune pipeline forecasts
Chapter 4 Competitive landscape
Summary
Introduction
Amgen
Overview
Sales focus by drug class
Marketed product portfolio
R&D pipeline analysis
Strategic and growth analysis
Drivers of growth
Resistors of growth
Johnson & Johnson
Overview
Sales focus by drug class
Marketed product portfolio
R&D pipeline analysis
Strategic and growth analysis
Drivers of growth
Resistors of growth
Pfizer
Overview
Sales focus by drug class
Marketed product portfolio
R&D pipeline analysis
Strategic and growth analysis
Drivers of growth
Resistors of growth
Novartis
Overview
Sales focus by drug class
Marketed product portfolio
R&D pipeline analysis
Strategic and growth analysis
Drivers of growth
Resistors of growth
Abbott
Overview
Sales focus by drug class
Marketed product portfolio
R&D pipeline analysis
Strategic and growth analysis
Drivers of growth
Resistors of growth
Wyeth
Overview
Sales focus by drug class
Marketed product portfolio
R&D pipeline analysis
Strategic and growth analysis
Drivers of growth
Resistors of growth
Roche
Overview
Sales focus by drug class
Marketed product portfolio
R&D pipeline analysis
Strategic and growth analysis
Drivers of growth
Resistors of growth
Astellas
Overview
Sales focus by drug class
Marketed product portfolio
R&D pipeline analysis
Strategic and growth analysis
Drivers of growth
Resistors of growth
Boehringer Ingleheim
Overview
Sales focus by drug class
Marketed product portfolio
R&D pipeline analysis
Strategic and growth analysis
Drivers of growth
Resistors of growth
Schering-Plough
Overview
Sales focus by drug class
Marketed product portfolio
R&D pipeline analysis
Strategic and growth analysis
Drivers of growth
Resistors of growth
Chapter 5 Appendix
IMS data
L4A0 Immunosuppressive agents
M1A1 Antirheumatics, non-steroidal plain
M1A2 Antirheumatics, non-steroidal combination
M1A3 Coxibs
M1B0 Antirheumatics, steroidal combination
M1C0 Specific anti-rheumatic agents
M2A0 Antirheumatics, topical
Index
List of Figures
Figure 1.1: Typical treatment patterns in the treatment of psoriasis
Figure 2.2: Global autoimmune market share by geography, 2006
Figure 2.3: Sales of types of autoimmune brands, 2005-06
Figure 2.4: Competitive dynamics of the global autoimmune market by drug class, 2006
Figure 2.5: Competitive dynamics of the leading 10 brands in the global autoimmune market, 2005-06
Figure 2.6: Competitive dynamics of the leading immunosuppressant treatments in the global autoimmune market, 2005-6
Figure 2.7: Competitive dynamics of the leading antirheumatic treatments in the global autoimmune market, 2005-6
Figure 2.8: Competitive dynamics of the leading NSAID treatments in the global autoimmune market, 2005-06
Figure 2.9: Competitive dynamics of the leading topical antirheumatic treatments in the global autoimmune market, 2005-06
Figure 2.10: Competitive dynamics of the leading COX-II treatments in the global autoimmune market, 2005-6
Figure 2.11: Competitive dynamics of the leading corticosteroid treatments in the global autoimmune market, 2005-06
Figure 3.12: Prevailing R&D approaches, 2006
Figure 3.13: The autoimmune pipeline by indication and stage of development, 2006
Figure 3.14: Leading recently launched products and late-stage R&D compounds indicated for the treatment of autoimmune disorders, 2006
Figure 4.15: Competitive dynamics of the leading players in the global autoimmune market
Figure 4.16: Amgen’s auto-immune sales, 2006
Figure 4.17: J&J’s autoimmune sales, 2006
Figure 4.18: Pfizer’s autoimmune sales, 2006
Figure 4.19: Novartis’ autoimmune sales by drug class, 2006
Figure 4.20: Abbott’s autoimmune sales by drug class, 2006
Figure 4.21: Wyeth’s autoimmune sales by drug class, 2006
Figure 4.22: Roche’s autoimmune sales by drug class, 2006
Figure 4.23: Astellas’ autoimmune salesby drug class, 2006
Figure 4.24: BI’s autoimmune salesby drug class, 2006
Figure 4.25: Schering-Plough’s autoimmune sales by drug class, 2006
List of Tables
Table 1.1: Estimated prevalence of autoimmune-related diseases in the seven major pharmaceutical markets, 2006
Table 1.2: Estimated prevalence of osteoarthritis across the seven major pharmaceutical markets, 2006
Table 1.3: Estimated prevalence of rheumatoid arthritis across the seven major pharmaceutical markets, 2006
Table 1.4: Forecast prevalence of OA across the seven major markets
Table 1.5: Forecast prevalence of RA across the seven major markets
Table 1.6: Estimated prevalence of ankylosing spondylitis across the seven major pharmaceutical markets, 2006
Table 1.7: Estimated prevalence of psoriatic arthritis across the seven major pharmaceutical markets, 2006
Table 1.8: Forecast prevalence of ankylosing spondylitis across the seven major markets, 2006–12
Table 1.9: Forecast prevalence of psoriatic arthritis across the seven major markets, 2006–12
Table 1.10: Estimated prevalence of lupus across the seven major pharmaceutical markets, 2006
Table 1.11: Forecast prevalence of lupus across the seven major markets, 2006–12
Table 1.12: Estimated prevalence of psoriasis across seven major markets, 2006
Table 1.13: Forecast prevalence of psoriasis across the seven major markets, 2006-12
Table 1.14: Estimated prevalence of Crohn’s disease in the seven major pharmaceutical markets, 2006
Table 1.15: Forecast prevalence of Crohn’s disease across the seven major markets, 2006–12
Table 2.16: Breakdown of the global autoimmune market by drug class, 2002-06
Table 2.17: Leading brands in the global autoimmune market, 2005–06
Table 2.18: Leading immunosuppressant brands in the global autoimmune market, 2005–06
Table 2.19: Immunosuppressive agents sales forecast, 2006-12
Table 2.20: Leading antirheumatic brands in the global autoimmune market, 2005–06
